Welcome to our dedicated page for Mirati Therapeut news (Ticker: MRTX), a resource for investors and traders seeking the latest updates and insights on Mirati Therapeut stock.
Mirati Therapeutics, Inc. (NASDAQ: MRTX) is a commercial-stage biopharmaceutical company developing precision medicines for cancer treatment. This page provides investors and researchers with essential updates on clinical trial progress, regulatory milestones, and corporate developments shaping the future of oncology care.
Discover authoritative coverage of Mirati's innovative pipeline including KRAZATI® (adagrasib) for KRASG12C-mutated cancers and novel inhibitors targeting PRMT5 and KRASG12D. Our curated news feed delivers timely updates on FDA interactions, partnership announcements, and financial strategies critical for informed decision-making.
Key focus areas include treatment efficacy data, international regulatory approvals, and strategic leadership updates. Bookmark this page to stay informed about developments impacting MRTX's position in precision oncology and access to emerging therapies for high-need patient populations.
Mirati Therapeutics (NASDAQ: MRTX) announced promising clinical data for adagrasib, a potent KRASG12C inhibitor, demonstrating efficacy in patients with advanced solid tumors such as pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancer (BTC). The findings, published in the Journal of Clinical Oncology and presented at the ASCO Plenary Series in April 2023, indicate an overall objective response rate (ORR) of 35%, with 33% for PDAC and 42% for BTC. Adagrasib's safety profile aligns with prior studies on NSCLC and CRC. This Phase 2 data from the KRYSTAL-1 study highlights adagrasib’s potential as a monotherapy, especially given its recent inclusion in the NCCN guidelines for CNS cancers, signaling a pathway toward regulatory approval for additional indications.
Mirati Therapeutics (NASDAQ: MRTX) will announce first quarter 2023 financial results on May 9, 2023, at 4:30 p.m. ET. The event will include corporate updates and a review of financial results. Investors can listen to the call via a live webcast on Mirati's website or by dialing specific U.S. and international phone numbers.
Mirati is committed to developing therapies for cancer, focusing on unmet needs in areas like lung cancer. The company is advancing several promising therapeutics, including KRAZATI® (adagrasib), which targets genetic drivers of cancer. However, investors are reminded that forward-looking statements in the release carry risks and uncertainties, including those associated with COVID-19 and drug development processes.
FAQ
What is the market cap of Mirati Therapeut (MRTX)?
